Geron Corp. (GERN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.57+3.97%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · GERN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
GERN — earnings in line
Dated 2026-08-06
and in the accompanying Exhibit 99.1 to this Current Report shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and shall not be incorporated by reference into any filing made by the Company with the U.S. Securities and Exchang…
Why it matters: A drop in sector revenue growth signals a slowdown, affecting Geron’s outlook.
Worry ifSector revenue growth is below its median for two quarters in a row.
Less concerning ifSector revenue growth remains above its median.
Why it matters: Keeping costs low is key for good finances and making money.
Supportive ifTotal operating costs were between $230 million and $240 million for Q3 2026.
Worry ifTotal operating costs are over $240 million in Q3 2026.
Why it matters: Revenue growth shows strong demand for RYTELO and good sales efforts.
Supportive ifQ3 RYTELO net product revenue growth exceeds 10% compared to Q2 2026.
Worry ifQ3 RYTELO net product revenue growth is less than 5% compared to Q2 2026.
Why it matters: This trial is important for Geron's plan to treat myelofibrosis.
Supportive ifLook for updates on patient enrollment or early data from the Phase 3 trial.
Worry ifNo updates or delays in the trial timeline are reported.
Why it matters: More access to RYTELO can greatly boost revenue and market share.
Supportive ifLook for news on a partnership or progress for RYTELO in a new market.
Worry ifNo news or delays in plans for RYTELO expansion outside the U.S.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$255 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $569 loss on $10,000 · 5.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,359 loss on $10,000 · 43.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.